Meglumine

CHEMBL1200570 Phase 4 Aprobado Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
195.2 g/mol
LogP
-2.8
Phase
4

An amino sugar used primarily as an excipient (inactive ingredient) to prepare water-soluble salts of various acidic drugs, improving their solubility and tolerability for pharmaceutical formulations. It is also a component of contrast agents used in radiological imaging.

Peso molecular

195,2100 g/mol

LogP

-2,80

TPSA

113,00 Ų

Regla de cinco de Lipinski

Cumple

Áreas terapéuticas

Mecanismo de acción

Enhances the contrast of specific tissues or structures during medical imaging procedures by altering the local signal intensity or X-ray absorption characteristics.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mecanismo

Enhances the contrast of specific tissues or structures during medical imaging procedures by altering the local signal intensity or X-ray absorption characteristics.

Estructura 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO

InChI

InChI=1S/C7H17NO5/c1-8-2-4(10)6(12)7(13)5(11)3-9/h4-13H,2-3H2,1H3/t4-,5+,6+,7+/m0/s1

Molecular Formula

C7H17NO5

HBD / HBA

6 / 6

Enlaces Rotables

6

Átomos Pesados

13

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Preguntas frecuentes

An amino sugar used primarily as an excipient (inactive ingredient) to prepare water-soluble salts of various acidic drugs, improving their solubility and tolerability for pharmaceutical formulations. It is also a component of contrast agents used in radiological imaging.

Enhances the contrast of specific tissues or structures during medical imaging procedures by altering the local signal intensity or X-ray absorption characteristics.

Yes, Meglumine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1200570. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 8567. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

Aviso médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.